AOTI Inc. (Advanced Oxygen Therapy Inc.) is a privately owned international medical technology company specializing in the development and provision of innovative solutions to resolve chronic and acute wounds. Their flagship product line, Topical Wound Oxygen (TWO2) therapy, offers non-invasive, multi-modality, adjunctive treatments designed to enhance healing, particularly for challenging conditions like diabetic foot ulcers and venous leg ulcers. AOTI is committed to improving patient outcomes and healthcare efficiency through clinically proven, cost-effective technologies that address the cycle of infection and inflammation.
Serves as the global headquarters, overseeing global strategy, research and development, manufacturing, clinical affairs, market access, and administrative operations for AOTI's advanced wound care technologies.
The facility supports R&D for medical device innovation, quality control, and corporate functions. While specific architectural details are not publicly highlighted, it is equipped for medical technology development and global operations management.
As a medical technology company focused on innovation and patient outcomes, the work culture at AOTI likely emphasizes collaboration, scientific rigor, ethical practices, and a strong commitment to quality. Employees are driven by the mission to improve the lives of patients with chronic wounds.
The Oceanside headquarters is pivotal to AOTI's mission, acting as the central hub for innovating, developing, and distributing its patented TWO2 therapy solutions worldwide. It represents the core of their efforts in advancing the wound care market.
AOTI supports its advanced wound care solutions globally with primary operational hubs in Oceanside, California (USA) and Galway, Ireland (European HQ). This strategic positioning facilitates international clinical trials, product distribution, sales and marketing initiatives, and comprehensive customer support across North America, Europe, and other targeted international markets. The company actively collaborates with healthcare professionals and institutions worldwide to advance the adoption and understanding of its TWO2 therapy.
3616 Ocean Ranch Blvd
Oceanside
California
USA
Address: Unit 6, Galway Business Park, Dangan, Galway, Ireland, H91 V0Y8
To lead AOTI's commercial operations, clinical engagement, regulatory compliance, and distribution network within Europe and adjacent markets, ensuring localized support and responsiveness to regional healthcare providers and patient needs.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, AOTI' leadership includes:
AOTI has been backed by several prominent investors over the years, including:
Over the past 12-18 months, AOTI has strategically expanded its executive leadership, notably with appointments in operations and global sales to bolster its growth trajectory and market penetration. No major executive departures have been publicly announced in the recent period.
Discover the tools AOTI uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
AOTI Inc. typically utilizes an email format consisting of the employee's first initial followed by their full last name, all before the '@aotinc.net' domain. This is a common pattern observed for their professional communications.
[first_initial][last]@aotinc.net
Format
hharalson@aotinc.net
Example
85%
Success rate
AOTI Inc. Website • April 23, 2024
AOTI announced the presentation of significant new clinical and health economic data for its Topical Wound Oxygen (TWO2) therapy at the Symposium on Advanced Wound Care (SAUWC) Spring 2024. The data further supports TWO2's efficacy in healing chronic wounds and its cost-effectiveness....more
AOTI Inc. Website • February 27, 2024
AOTI highlighted its participation in the Diabetic Foot Global Conference (DFCon24), where it showcased its unique multi-modality Topical Wound Oxygen (TWO2) therapy for treating complex diabetic foot ulcers, emphasizing its role in comprehensive diabetic limb preservation strategies....more
AOTI Inc. Website • December 5, 2023
AOTI announced that the U.S. Patent and Trademark Office (USPTO) issued a new patent covering its unique multi-modality approach for its Topical Wound Oxygen (TWO2) therapy. This patent further strengthens AOTI's intellectual property portfolio for its innovative wound care solutions....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including AOTI, are just a search away.